small molecule

LIPFENDRA

ENLICITIDE DECANOATE

Loss of exclusivityFebruary 2040latest FDA-listed patent expiry

CompanyMERCK SHARP AND DOHME LLC

Drug detail

Brand name	LIPFENDRA
Active ingredient	ENLICITIDE DECANOATE
Strength	EQ 20MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
11427616	February 2040	substance, product

Regulatory exclusivity

Code	Expires
NCE	July 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from MERCK SHARP AND DOHME LLC